Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (3458)	10/31/2002 9:01:05 AM
From: biostruggle	Read Replies (1) \| Respond to of 10345

Well Elan survive as an independent company? If Armen can maintain 400 ml revenue and get an additional 2 billion on remaining asset sales, then Elan can pay down all debt (cv bonds+QSPE + prod payments) and cover cash burn (200 million/yr) til antegren comes out end of 2005. If Elan comes up with less, then it has to role over cv debt with cash +stock. How much cash = how much less than 2 bill realized. No antegren, no company. Realistically. Elan will raise enough cash to cover CV bonds and put the company up for sale. How much Elan will get for antegren potential + alz potential - remaining debt (QSPE 850+ 650) is open question. Other risk factors. SEC comes down on Elan and sets up torts to finish off the company. Geaney has taken good company and in 1.5 years of financial engineering drove it into the ground.

To: Icebrg who wrote (3458)	11/5/2002 8:10:49 AM
From: Icebrg	Read Replies (1) \| Respond to of 10345

Compounds Demonstrate Significant Potential for Treating Parkinson's Disease and Other Neurological Disorders CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 5, 2002--Curis, Inc (NASDAQ:CRIS - News) scientists presented studies at the recent 32nd Annual Society for Neurosciences meeting which demonstrated the potential of Curis' research work on small molecule Hedgehog nerve stimulants (Hh agonists) to treat a broad array of neurological disorders, including Parkinson's Disease, Huntington's Disease and stroke. These findings extend previous positive results with Hedgehog proteins and identify additional beneficial effects. In animal tests, mice treated with Curis Hedgehog agonists showed significant improvement both in biochemical measures of brain recovery and in multiple assays of behavioral recovery. These proprietary Hh agonists were effective when given to animals either as a pre- or post-treatment for Parkinson's or a pre-treatment for Huntington's. They also demonstrated the ability to reduce damage to the brain in specific types of stroke, when given either before or after the initiation of the stroke event. Additionally, Hh agonists were found to potentially activate the production of new brain cells in the areas of the adult brain containing neurostem cells. "These exciting findings demonstrate the therapeutic potential of Hedgehog agonists for Parkinson's Disease and other disorders," said Daniel R. Passeri, President and Chief Executive Officer of Curis. We believe the strong positive results from these new studies confirm the value of Curis' approach and further support our intention to bring our small-molecule candidates to the next stage of drug development." Complete copies of the material provided by Curis at the 32nd Annual Society for Neurosciences meeting are available on request to the Company and can be seen online at jbiol.com. On July 18, 2001, Curis announced that it had formed a business venture with Elan Corporation, Plc (Elan) committed to the research and development of molecules that stimulate the Hedgehog signaling pathway. The business venture is focused upon the development of therapeutics targeting a number of neurological disorders, including Parkinson's Disease.